Gelteq Ltd Shares Surge on Positive Preclinical Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 14 Jan 26
Source: Benzinga
Gelteq Ltd (NASDAQ:GELS) shares surged 69.25% in pre-market trading as the stock crossed above its 5-day SMA.
The surge is attributed to positive preclinical results showing a 22% increase in CBD bioavailability compared to an FDA-approved oil-based product, which enhances Gelteq's competitive edge. Additionally, the company plans to utilize Australia's Special Access Scheme for quicker market entry, potentially increasing revenue and partnership opportunities in the medicinal cannabis sector.
This significant price movement indicates a strong market interest in Gelteq's innovative oral gel platform, suggesting a positive outlook for the company's future growth and market positioning.
Analyst Views on GELS
About GELS
Gelteq Limited is an Australia-based clinical and science-based company. The Company is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The Company offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The Company also offers a versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
